Altamira Therapeutics (CYTO) Enters ATM Agreement

On January 19, 2024, Altamira Therapeutics (NASDAQ: CYTO) entered into an At the Market Offering Agreement (the “Agreement”) with H.C. Wainwright & Co., LLC (“HCW”), as sales agent or principal, relating to the offer and sale of the Company’s common shares, par value $0.002 per share, from time to time, having an aggregate offering amount of up to $1.66 million (the “Offering”). On January 19, 2024, pursuant to the Agreement, the Company filed a prospectus supplement (the “Prospectus Supplement”), including an accompanying base prospectus, dated December 8, 2021, forming a part of its effective registration statement on Form F-3 (File No. 333-261127), initially filed with the Securities and Exchange Commission on November 16, 2021.

The sales of common shares, if any, under the Agreement will be made at market prices by any method deemed to be an “at the market offering” as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended, including sales made directly on the Nasdaq Capital Market, on any other existing trading market for the Company’s common shares, or to or through a market maker. Pursuant to the Agreement, HCW will be entitled to 3.0% of the gross sales price of the common shares sold in the Offering. Because there are no minimum sale requirements as a condition to the Offering, the actual total dollar amount and number of common shares sold, commissions and net proceeds to the Company, if any, are not determinable at this time. The actual dollar amount and number of common shares sold through the Agreement and the Prospectus Supplement, if any, will be dependent, among other things, on market conditions and the Company’s capital raising requirements. The Company has no obligation to sell, and HCW is not obligated to buy or sell, any of the common shares under the Agreement and may at any time suspend offers under the Agreement or terminate the Agreement. The Offering will terminate upon the earlier of (i) the sale of common shares pursuant to the Prospectus Supplement having an aggregate offering amount of $1.66 million and (ii) the termination by the Company or HCW of the Agreement pursuant to its terms.

The foregoing summary of the Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Agreement which is included as Exhibit 1.1 hereto and incorporated herein by reference.

You May Also Be Interested In

• NXG Cushing Midstream Energy Fund launches at-market share offering
• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Plastec Technologies to dissolve, pays $0.39 final dividend